

## Income statement

### Three months ended 30th September 2009

	Results before major restructuring £m	Major restructuring £m	Total £m	Results before major restructuring \$m	Major restructuring \$m	Total \$m
<b>TURNOVER</b>	<b>6,758</b>	-	<b>6,758</b>	<b>10,948</b>	-	<b>10,948</b>
Cost of sales	(1,732)	(50)	(1,782)	(2,797)	(86)	(2,883)
Gross profit	5,026	(50)	4,976	8,151	(86)	8,065
Selling, general and administration	(2,064)	(82)	(2,146)	(3,353)	(132)	(3,485)
Research and development	(862)	(20)	(882)	(1,407)	(35)	(1,442)
Other operating income	123	-	123	207	-	207
<b>OPERATING PROFIT</b>	<b>2,223</b>	<b>(152)</b>	<b>2,071</b>	<b>3,598</b>	<b>(253)</b>	<b>3,345</b>
Finance income	19	-	19	31	-	31
Finance expense	(199)	-	(199)	(321)	-	(321)
Profit on disposal of interest in associate	-	-	-	4	-	4
Share of after tax profits of associates and joint ventures	22	-	22	35	-	35
<b>PROFIT BEFORE TAXATION</b>	<b>2,065</b>	<b>(152)</b>	<b>1,913</b>	<b>3,347</b>	<b>(253)</b>	<b>3,094</b>
Taxation	(585)	43	(542)	(949)	71	(878)
<b>PROFIT AFTER TAXATION FOR THE PERIOD</b>	<b>1,480</b>	<b>(109)</b>	<b>1,371</b>	<b>2,398</b>	<b>(182)</b>	<b>2,216</b>
Profit attributable to minority interests	36	-	36	58	-	58
Profit attributable to shareholders	1,444	(109)	1,335	2,340	(182)	2,158
	1,480	(109)	1,371	2,398	(182)	2,216
<b>EARNINGS PER SHARE</b>	<b>28.5p</b>		<b>26.3p</b>	<b>46.2¢</b>	-	<b>42.6¢</b>
Diluted earnings per share	28.3p		26.1p	45.8¢	-	42.3¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

## Income statement

### Nine months ended 30th September 2009

	Results before major restructuring £m	Major restructuring £m	Total £m	Results before major restructuring \$m	Major restructuring \$m	Total \$m
<b>TURNOVER</b>	<b>20,274</b>	-	<b>20,274</b>	<b>31,222</b>	-	<b>31,222</b>
Cost of sales	(4,997)	(264)	(5,261)	(7,695)	(407)	(8,102)
Gross profit	15,277	(264)	15,013	23,527	(407)	23,120
Selling, general and administration	(6,420)	(218)	(6,638)	(9,887)	(336)	(10,223)
Research and development	(2,859)	(120)	(2,979)	(4,403)	(185)	(4,588)
Other operating income	582	-	582	896	-	896
	<b>6,580</b>	<b>(602)</b>	<b>5,978</b>	<b>10,133</b>	<b>(928)</b>	<b>9,205</b>
<b>OPERATING PROFIT</b>						
Finance income	65	-	65	100	-	100
Finance expense	(567)	(3)	(570)	(873)	(5)	(878)
Profit on disposal of interest in associate	115	-	115	177	-	177
Share of after tax profits of associates and joint ventures	53	-	53	82	-	82
	<b>6,246</b>	<b>(605)</b>	<b>5,641</b>	<b>9,619</b>	<b>(933)</b>	<b>8,686</b>
<b>PROFIT BEFORE TAXATION</b>						
Taxation	(1,797)	157	(1,640)	(2,767)	242	(2,525)
	<b>4,449</b>	<b>(448)</b>	<b>4,001</b>	<b>6,852</b>	<b>(691)</b>	<b>6,161</b>
<b>PROFIT AFTER TAXATION FOR THE PERIOD</b>						
Profit attributable to minority interests	100	-	100	154	-	154
Profit attributable to shareholders	4,349	(448)	3,901	6,698	(691)	6,007
	<b>4,449</b>	<b>(448)</b>	<b>4,001</b>	<b>6,852</b>	<b>(691)</b>	<b>6,161</b>
<b>EARNINGS PER SHARE</b>	<b>85.8p</b>		<b>77.0p</b>	<b>132.1¢</b>		<b>118.6¢</b>
Diluted earnings per share	85.2p		76.4p	131.2¢		117.7¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

## Turnover

### Pharmaceuticals

Three months ended 30th September 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
<b>Respiratory</b>	<b>1,594</b>	<b>744</b>	<b>511</b>	<b>339</b>	<b>2,593</b>	<b>1,212</b>	<b>831</b>	<b>550</b>
<i>Avamys/Veramyst</i>	31	15	9	7	51	25	15	11
<i>Flixonase/Flonase</i>	28	3	9	16	47	5	15	27
<i>Flixotide/Flovent</i>	169	85	38	46	276	139	63	74
<i>Seretide/Advair</i>	1,152	587	378	187	1,872	957	613	302
<i>Serevent</i>	54	16	27	11	88	26	44	18
<i>Ventolin</i>	110	35	35	40	179	57	57	65
<i>Zyrtec</i>	18	-	-	18	29	-	-	29
<b>Anti-virals</b>	<b>1,049</b>	<b>500</b>	<b>247</b>	<b>302</b>	<b>1,698</b>	<b>809</b>	<b>404</b>	<b>485</b>
<b>HIV</b>	<b>392</b>	<b>168</b>	<b>155</b>	<b>69</b>	<b>635</b>	<b>274</b>	<b>251</b>	<b>110</b>
<i>Agenerase, Lexiva</i>	43	24	15	4	69	39	24	6
<i>Combivir</i>	102	43	36	23	166	71	59	36
<i>Epivir</i>	34	12	12	10	54	19	19	16
<i>Epzicom/Kivexa</i>	131	52	60	19	212	84	98	30
<i>Trizivir</i>	48	23	19	6	78	38	31	9
<i>Ziagen</i>	26	13	8	5	42	21	13	8
<i>Valtrex</i>	349	265	38	46	566	430	61	75
<i>Relenza</i>	182	45	38	99	292	71	64	157
<i>Zeffix</i>	54	4	7	43	87	7	11	69
<b>Central nervous system</b>	<b>418</b>	<b>115</b>	<b>139</b>	<b>164</b>	<b>681</b>	<b>191</b>	<b>226</b>	<b>264</b>
<i>Imigran/Imitrex</i>	53	19	23	11	87	32	37	18
<i>Lamictal</i>	121	64	38	19	196	104	61	31
<i>Requip</i>	43	(4)	34	13	70	(6)	55	21
<i>Requip XL</i>	31	7	23	1	50	12	36	2
<i>Seroxat/Paxil</i>	120	5	22	93	195	9	36	150
<i>Treximet</i>	15	15	-	-	24	24	-	-
<i>Wellbutrin/Wellbutrin XL</i>	16	4	8	4	28	9	13	6
<b>Cardiovascular and urogenital</b>	<b>552</b>	<b>336</b>	<b>142</b>	<b>74</b>	<b>896</b>	<b>546</b>	<b>230</b>	<b>120</b>
<i>Arixtra</i>	60	32	24	4	97	52	39	6
<i>Avodart</i>	131	80	36	15	212	129	59	24
<i>Coreg, Coreg CR</i>	39	39	-	-	64	64	-	-
<i>Fraxiparine</i>	56	-	42	14	90	-	68	22
<i>Levitra</i>	20	18	1	1	32	29	1	2
<i>Lovaza</i>	111	111	-	-	179	179	-	-
<i>Vesicare</i>	25	25	-	-	41	41	-	-
<i>Volibris</i>	6	-	5	1	9	-	7	2
<b>Metabolic</b>	<b>284</b>	<b>132</b>	<b>67</b>	<b>85</b>	<b>461</b>	<b>215</b>	<b>108</b>	<b>138</b>
<i>Avandia products</i>	185	97	42	46	300	158	68	74
<i>Avandia</i>	108	62	16	30	176	102	26	48
<i>Avandamet</i>	66	29	25	12	106	47	40	19
<i>Bonviva/Boniva</i>	60	35	22	3	98	58	36	4
<b>Anti-bacterials</b>	<b>376</b>	<b>39</b>	<b>146</b>	<b>191</b>	<b>612</b>	<b>64</b>	<b>238</b>	<b>310</b>
<i>Augmentin</i>	162	9	68	85	263	16	110	137
<b>Oncology and emesis</b>	<b>149</b>	<b>64</b>	<b>51</b>	<b>34</b>	<b>242</b>	<b>105</b>	<b>83</b>	<b>54</b>
<i>Hycamtin</i>	41	24	14	3	67	39	23	5
<i>Promacta</i>	3	3	-	-	4	4	-	-
<i>Tyverb/Tykerb</i>	46	12	19	15	73	20	30	23
<i>Zofran</i>	23	(1)	12	12	38	(1)	20	19
<b>Vaccines</b>	<b>802</b>	<b>206</b>	<b>344</b>	<b>252</b>	<b>1,290</b>	<b>329</b>	<b>554</b>	<b>407</b>
<i>Boostrix</i>	39	24	11	4	62	38	18	6
<i>Cervarix</i>	28	-	17	11	47	-	30	17
<i>Fluarix, FluLaval</i>	147	63	60	24	227	98	92	37
<i>Flu Pre-Pandemic</i>	11	-	4	7	18	1	7	10
<i>Hepatitis</i>	170	67	65	38	276	109	105	62
<i>Infanrix, Pediarix</i>	167	30	105	32	270	49	170	51
<i>Rotarix</i>	84	22	14	48	134	36	22	76
<i>Synflorix</i>	13	-	11	2	21	-	18	3
<b>Other</b>	<b>258</b>	<b>7</b>	<b>87</b>	<b>164</b>	<b>417</b>	<b>12</b>	<b>140</b>	<b>265</b>
	<b>5,482</b>	<b>2,143</b>	<b>1,734</b>	<b>1,605</b>	<b>8,890</b>	<b>3,483</b>	<b>2,814</b>	<b>2,593</b>
Stiefel products	111				171			
	<b>5,593</b>				<b>9,061</b>			

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

## Turnover

### Pharmaceuticals

Nine months ended 30th September 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
<b>Respiratory</b>	<b>5,063</b>	<b>2,413</b>	<b>1,607</b>	<b>1,043</b>	<b>7,797</b>	<b>3,716</b>	<b>2,475</b>	<b>1,606</b>
<i>Avamys/Veramyst</i>	109	53	34	22	168	82	52	34
<i>Flixonase/Flonase</i>	136	21	33	82	209	32	51	126
<i>Flixotide/Flovent</i>	553	281	129	143	852	433	199	220
<i>Seretide/Advair</i>	3,611	1,888	1,173	550	5,561	2,908	1,806	847
<i>Serevent</i>	175	53	87	35	270	82	134	54
<i>Ventolin</i>	338	105	108	125	521	162	166	193
<i>Zyrtec</i>	53	-	-	53	82	-	-	82
<b>Anti-virals</b>	<b>3,117</b>	<b>1,484</b>	<b>823</b>	<b>810</b>	<b>4,800</b>	<b>2,285</b>	<b>1,268</b>	<b>1,247</b>
<b>HIV</b>	<b>1,193</b>	<b>527</b>	<b>480</b>	<b>186</b>	<b>1,837</b>	<b>812</b>	<b>739</b>	<b>286</b>
<i>Agenerase, Lexiva</i>	134	74	48	12	206	114	74	18
<i>Combivir</i>	316	140	114	62	487	216	176	95
<i>Epivir</i>	99	36	38	25	152	55	58	39
<i>Epzicom/Kivexa</i>	397	160	181	56	611	246	279	86
<i>Trizivir</i>	152	78	63	11	234	120	97	17
<i>Ziagen</i>	78	38	26	14	120	58	40	22
<i>Valtrex</i>	1,072	813	119	140	1,651	1,252	183	216
<i>Relenza</i>	464	75	173	216	715	116	266	333
<i>Zeffix</i>	162	13	22	127	249	20	34	195
<b>Central nervous system</b>	<b>1,366</b>	<b>473</b>	<b>428</b>	<b>465</b>	<b>2,103</b>	<b>728</b>	<b>659</b>	<b>716</b>
<i>Imigran/Imitrex</i>	185	80	71	34	285	123	109	53
<i>Lamictal</i>	368	195	115	58	567	300	177	90
<i>Requip</i>	144	10	101	33	222	15	156	51
<i>Requip XL</i>	83	20	62	1	128	31	95	2
<i>Seroxat/Paxil</i>	384	32	77	275	591	49	119	423
<i>Treximet</i>	41	41	-	-	63	63	-	-
<i>Wellbutrin/Wellbutrin XL</i>	110	78	21	11	169	120	32	17
<b>Cardiovascular and urogenital</b>	<b>1,683</b>	<b>1,040</b>	<b>428</b>	<b>215</b>	<b>2,592</b>	<b>1,602</b>	<b>659</b>	<b>331</b>
<i>Arixtra</i>	180	98	69	13	277	151	106	20
<i>Avodart</i>	387	236	109	42	596	363	168	65
<i>Coreg, Coreg CR</i>	141	140	-	1	217	215	-	2
<i>Fraxiparine</i>	169	-	128	41	260	-	197	63
<i>Levitra</i>	58	54	3	1	89	83	4	2
<i>Lovaza</i>	321	320	-	1	494	492	-	2
<i>Vesicare</i>	75	75	-	-	116	116	-	-
<i>Volibris</i>	12	-	11	1	18	-	16	2
<b>Metabolic</b>	<b>881</b>	<b>431</b>	<b>206</b>	<b>244</b>	<b>1,357</b>	<b>664</b>	<b>317</b>	<b>376</b>
<i>Avandia products</i>	580	316	131	133	893	486	202	205
<i>Avandia</i>	350	207	52	91	539	319	80	140
<i>Avandamet</i>	199	89	75	35	306	137	115	54
<i>Bonviva/Boniva</i>	188	114	66	8	290	176	102	12
<b>Anti-bacterials</b>	<b>1,183</b>	<b>132</b>	<b>481</b>	<b>570</b>	<b>1,822</b>	<b>203</b>	<b>741</b>	<b>878</b>
<i>Augmentin</i>	494	36	213	245	761	56	328	377
<b>Oncology and emesis</b>	<b>459</b>	<b>222</b>	<b>152</b>	<b>85</b>	<b>707</b>	<b>342</b>	<b>234</b>	<b>131</b>
<i>Hycamtin</i>	127	74	44	9	196	114	68	14
<i>Promacta</i>	8	8	-	-	12	12	-	-
<i>Tyverb/Tykerb</i>	121	40	54	27	186	62	83	41
<i>Zofran</i>	85	10	40	35	131	15	62	54
<b>Vaccines</b>	<b>2,183</b>	<b>521</b>	<b>950</b>	<b>712</b>	<b>3,362</b>	<b>802</b>	<b>1,463</b>	<b>1,097</b>
<i>Bostrix</i>	104	56	29	19	160	86	45	29
<i>Cervarix</i>	149	-	119	30	229	-	183	46
<i>Fluarix, FluLaval</i>	169	68	60	41	260	105	92	63
Flu Pre-Pandemic	47	25	14	8	72	38	22	12
Hepatitis	514	206	198	110	792	317	305	170
<i>Infanrix, Pediarix</i>	496	107	305	84	764	165	470	129
<i>Rotarix</i>	212	59	39	114	326	91	60	175
<i>Synflorix</i>	25	-	21	4	39	-	33	6
<b>Other</b>	<b>752</b>	<b>14</b>	<b>245</b>	<b>493</b>	<b>1,158</b>	<b>22</b>	<b>377</b>	<b>759</b>
	<b>16,687</b>	<b>6,730</b>	<b>5,320</b>	<b>4,637</b>	<b>25,698</b>	<b>10,364</b>	<b>8,193</b>	<b>7,141</b>
Stiefel products	111				171			
	<b>16,798</b>				<b>25,869</b>			

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

## Turnover

### Consumer Healthcare Three months ended 30th September 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
<b>Over-the-counter medicines</b>	<b>567</b>	<b>174</b>	<b>186</b>	<b>207</b>	<b>919</b>	<b>282</b>	<b>301</b>	<b>336</b>
<i>alli</i>	49	20	29	-	80	33	47	-
<i>Breathe Right</i>	23	15	5	3	37	24	8	5
Cold sore franchise	28	17	9	2	44	27	14	3
<i>Nicotene</i> replacement therapy	79	58	13	8	128	94	21	13
<i>Panadol</i>	96	-	26	70	155	-	42	113
<i>Tums</i>	25	20	1	4	40	32	2	6
<b>Oral healthcare</b>	<b>375</b>	<b>75</b>	<b>190</b>	<b>110</b>	<b>607</b>	<b>122</b>	<b>308</b>	<b>177</b>
<i>Aquafresh franchise</i>	126	23	75	28	204	38	121	45
<i>Biotene</i>	7	4	1	2	11	6	2	3
Dental care	85	19	32	34	137	31	52	54
<i>Sensodyne franchise</i>	118	28	48	42	190	45	78	67
<b>Nutritional healthcare</b>	<b>223</b>	<b>-</b>	<b>125</b>	<b>98</b>	<b>360</b>	<b>-</b>	<b>201</b>	<b>159</b>
<i>Horlicks</i>	64	-	4	60	104	-	7	97
<i>Lucozade</i>	104	-	92	12	168	-	149	19
<i>Ribena</i>	40	-	29	11	65	-	47	18
	<b>1,165</b>	<b>249</b>	<b>501</b>	<b>415</b>	<b>1,886</b>	<b>404</b>	<b>810</b>	<b>672</b>

## Turnover

### Consumer Healthcare Nine months ended 30th September 2009

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
<b>Over-the-counter medicines</b>	<b>1,707</b>	<b>537</b>	<b>527</b>	<b>643</b>	<b>2,629</b>	<b>827</b>	<b>812</b>	<b>990</b>
<i>alli</i>	163	74	88	1	251	114	135	2
<i>Breathe Right</i>	70	39	17	14	108	60	26	22
Cold sore franchise	71	35	28	8	109	54	43	12
<i>Nicotene</i> replacement therapy	249	184	45	20	383	283	69	31
<i>Panadol</i>	289	-	66	223	445	-	102	343
<i>Tums</i>	80	69	1	10	123	106	2	15
<b>Oral healthcare</b>	<b>1,109</b>	<b>224</b>	<b>564</b>	<b>321</b>	<b>1,708</b>	<b>345</b>	<b>869</b>	<b>494</b>
<i>Aquafresh franchise</i>	375	71	219	85	578	110	337	131
<i>Biotene</i>	19	14	2	3	29	21	3	5
Dental care	249	58	92	99	383	89	142	152
<i>Sensodyne franchise</i>	343	77	145	121	528	119	223	186
<b>Nutritional healthcare</b>	<b>660</b>	<b>-</b>	<b>350</b>	<b>310</b>	<b>1,016</b>	<b>-</b>	<b>539</b>	<b>477</b>
<i>Horlicks</i>	200	-	13	187	308	-	20	288
<i>Lucozade</i>	290	-	249	41	447	-	384	63
<i>Ribena</i>	122	-	87	35	188	-	134	54
	<b>3,476</b>	<b>761</b>	<b>1,441</b>	<b>1,274</b>	<b>5,353</b>	<b>1,172</b>	<b>2,220</b>	<b>1,961</b>

## Balance sheet

	30th September 2009 £m	30th September 2009 \$m
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	9,380	15,008
Goodwill	3,294	5,270
Other intangible assets	7,261	11,618
Investments in associates and joint ventures	511	818
Other investments	558	893
Deferred tax assets	2,397	3,835
Derivative financial instruments	89	142
Other non-current assets	616	986
<b>Total non-current assets</b>	<b>24,106</b>	<b>38,570</b>
<b>Current assets</b>		
Inventories	4,193	6,709
Current tax recoverable	52	83
Trade and other receivables	6,050	9,680
Derivative financial instruments	288	461
Liquid investments	274	438
Cash and cash equivalents	6,467	10,347
Assets held for sale	17	27
<b>Total current assets</b>	<b>17,341</b>	<b>27,745</b>
<b>TOTAL ASSETS</b>	<b>41,447</b>	<b>66,315</b>
<b>LIABILITIES</b>		
<b>Current liabilities</b>		
Short-term borrowings	(1,886)	(3,018)
Trade and other payables	(6,084)	(9,734)
Derivative financial instruments	(241)	(386)
Current tax payable	(1,179)	(1,886)
Short-term provisions	(1,730)	(2,768)
<b>Total current liabilities</b>	<b>(11,120)</b>	<b>(17,792)</b>
<b>Non-current liabilities</b>		
Long-term borrowings	(15,035)	(24,056)
Deferred tax liabilities	(691)	(1,106)
Pensions and other post-employment benefits	(3,335)	(5,336)
Other provisions	(1,187)	(1,899)
Other non-current liabilities	(445)	(712)
<b>Total non-current liabilities</b>	<b>(20,693)</b>	<b>(33,109)</b>
<b>TOTAL LIABILITIES</b>	<b>(31,813)</b>	<b>(50,901)</b>
<b>NET ASSETS</b>	<b>9,634</b>	<b>15,414</b>
<b>EQUITY</b>		
Share capital	1,416	2,266
Share premium account	1,344	2,150
Retained earnings	5,701	9,122
Other reserves	819	1,310
<b>Shareholders' equity</b>	<b>9,280</b>	<b>14,848</b>
Minority interests	354	566
<b>TOTAL EQUITY</b>	<b>9,634</b>	<b>15,414</b>

US dollar amounts shown above are a convenience transaction of the sterling amounts using the period end rate of £1/\$1.60.